Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David S. who wrote (3173)	12/6/1997 6:47:00 PM
From: biao luo	Read Replies (2) of 6136

Agouron didn't invent Viracept. I just read this from a industry publication. The drug came out of Lilly's compound library. You could argue: so what? I am just commenting that this may be an indication how strong they are at the structural based design. I am not familar with the development of the drug. But if it really came out of Lilly library, I would presume structual based design played a minor role. Then I would start to doubt if they are as good as people have assumed on rational drug design. This may concern me about their pipeline. However, the company seems to have superb business and management sense. biao Disclaimer: I am a VRTX holder.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next